Takeda to Study Prosetta Biosciences' CNS Compounds

Written By John Flores

Takeda Pharmaceutical will partner with Prosetta Biosciences on a feasibility study for possible future co-development of Prosetta’s novel compounds for diseases and disorders of the central nervous system. Read more here.

John Flores https://boxc.ar
Previous

Prosetta gets a mention in Nature Medicine